Article
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Respiratory investigation - 1 May 2021
Hotta Takamasa, Tsubata Yukari, Hamai Kosuke, Tanino Akari, Kobayashi Misato, Nakamura Atsushi, Sugisaka Jun, Hongoh Masafumi, Ishihara Noriyuki, Ishikawa Nobuhisa, Yamasaki Masahiro, Fujitaka Kazunori, Kubota Tetsuya, Nishimura Nobuhiro, Isobe Takeshi
Abstract excerpt
BACKGROUND: The risk of venous thromboembolism (VTE) is increased 7-fold in patients with cancer than in those without. Low-molecular-weight heparin is the standard treatment for cancer-associated VTE. Direct oral anticoagulants (DOACs) are not inferior to low-molecular-weight heparin with respect to the general outcome of recurrent VTE. Warfarin is associated with a risk of bleeding when used in combination with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.